Your browser doesn't support javascript.
loading
CD4+ T cell immunity against cutaneous melanoma encompasses multifaceted MHC II-dependent responses.
Bawden, Emma G; Wagner, Teagan; Schröder, Jan; Effern, Maike; Hinze, Daniel; Newland, Lewis; Attrill, Grace H; Lee, Ariane R; Engel, Sven; Freestone, David; de Lima Moreira, Marcela; Gressier, Elise; McBain, Nathan; Bachem, Annabell; Haque, Ashraful; Dong, Ruining; Ferguson, Angela L; Edwards, Jarem J; Ferguson, Peter M; Scolyer, Richard A; Wilmott, James S; Jewell, Christopher M; Brooks, Andrew G; Gyorki, David E; Palendira, Umaimainthan; Bedoui, Sammy; Waithman, Jason; Hochheiser, Katharina; Hölzel, Michael; Gebhardt, Thomas.
Afiliação
  • Bawden EG; Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
  • Wagner T; Institute of Experimental Oncology (IEO), Medical Faculty, University Hospital Bonn, University of Bonn, Bonn 53105, Germany.
  • Schröder J; Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
  • Effern M; Computational Sciences Initiative, Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia.
  • Hinze D; Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
  • Newland L; Institute of Experimental Oncology (IEO), Medical Faculty, University Hospital Bonn, University of Bonn, Bonn 53105, Germany.
  • Attrill GH; Institute of Experimental Oncology (IEO), Medical Faculty, University Hospital Bonn, University of Bonn, Bonn 53105, Germany.
  • Lee AR; Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
  • Engel S; Institute of Experimental Oncology (IEO), Medical Faculty, University Hospital Bonn, University of Bonn, Bonn 53105, Germany.
  • Freestone D; Melanoma Institute Australia, University of Sydney, Sydney, NSW, Australia.
  • de Lima Moreira M; Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.
  • Gressier E; Charles Perkins Centre, University of Sydney, Sydney, NSW, Australia.
  • McBain N; Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
  • Bachem A; Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
  • Haque A; Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
  • Dong R; Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
  • Ferguson AL; Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
  • Edwards JJ; Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
  • Ferguson PM; Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
  • Scolyer RA; Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
  • Wilmott JS; Computational Sciences Initiative, Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia.
  • Jewell CM; Department of Clinical Pathology and Centre for Cancer Research, University of Melbourne, Melbourne, VIC, Australia.
  • Brooks AG; Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.
  • Gyorki DE; Charles Perkins Centre, University of Sydney, Sydney, NSW, Australia.
  • Palendira U; Centenary Institute, University of Sydney, Sydney, NSW, Australia.
  • Bedoui S; Infection, Immunity and Inflammation theme, School of Medical Sciences, Charles Perkins Centre, University of Sydney, Sydney, NSW, Australia.
  • Waithman J; Melanoma Institute Australia, University of Sydney, Sydney, NSW, Australia.
  • Hochheiser K; Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.
  • Hölzel M; Charles Perkins Centre, University of Sydney, Sydney, NSW, Australia.
  • Gebhardt T; Melanoma Institute Australia, University of Sydney, Sydney, NSW, Australia.
Sci Immunol ; 9(91): eadi9517, 2024 Jan 19.
Article em En | MEDLINE | ID: mdl-38241401
ABSTRACT
Whereas CD4+ T cells conventionally mediate antitumor immunity by providing help to CD8+ T cells, recent clinical studies have implied an important role for cytotoxic CD4+ T cells in cancer immunity. Using an orthotopic melanoma model, we provide a detailed account of antitumoral CD4+ T cell responses and their regulation by major histocompatibility complex class II (MHC II) in the skin. Intravital imaging revealed prominent interactions of CD4+ T cells with tumor debris-laden MHC II+ host antigen-presenting cells that accumulated around tumor cell nests, although direct recognition of MHC II+ melanoma cells alone could also promote CD4+ T cell control. CD4+ T cells stably suppressed or eradicated tumors even in the absence of other lymphocytes by using tumor necrosis factor-α and Fas ligand (FasL) but not perforin-mediated cytotoxicity. Interferon-γ was critical for protection, acting both directly on melanoma cells and via induction of nitric oxide synthase in myeloid cells. Our results illustrate multifaceted and context-specific aspects of MHC II-dependent CD4+ T cell immunity against cutaneous melanoma, emphasizing modulation of this axis as a potential avenue for immunotherapies.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Melanoma Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Melanoma Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article